The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

"The global CNS disorders market expanded by 8.0% from 2006, to reach total sales of $77.3bn in 2007. This growth has been primarily driven by treatments for AD, ADHD and Parkinson’s Disease."

The CNS disorders market is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms continue to be favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs. High levels of investment have contributued to a rich product pipeline, with an estimated 600 clinical candidates currently under development, and companies are widely engaged in licensing novel/clinically differentiated CNS products. The sector has struggled recently however, with previously dominant product classes coming under increasing pressure from generic competition and safety concerns. ‘The CNS Market Outlook to 2013’ is a new report published by Business Insights that provides comprehensive coverage of the major markets within the global CNS disorders market, incorporating a detailed epidemiological analysis of major indications and key factors impacting their prevalence. This report profiles the factors and underlying trends shaping the market landscape and identifies the most promising areas of potential growth. Current leading brands of treatment within each indication are assessed and ten of the market’s leading players are profiled. Sales forecasts for currently marketed and key pipeline products over the 2008-13 period are also provided. Discover the key trends and growth drivers of the CNS market, assess the competitive dynamics of leading companies and evaluate the future prospects of pipeline products with this report...

Assess the competitive dynamics of leading companies and evaluate the future prospects of pipeline products within the CNS disorders market...

Use this new report to...

Assess epidemiology, treatment trends and sales patterns for treatment markets including depression, schizophrenia, AD, migraine, epilepsy, PD, insomnia and ADHD across major countries including the UK, Japan, France, Germany, Italy, Spain and
the US.

Measure the market performance and strategic positioning of major CNS developers with this report’s evaluation of the franchises and market shares of AstraZeneca, Eli Lilly, Eisai, Forest, GSK, J&J, Novartis, Pfizer, Sanofi Aventis and Wyeth.

Understand the market dynamics of the global CNS disorders area and identify the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.

Predict revenues for major currently marketed and pipeline CNS products over 2008-13, with this report’s sales forecasts across major indications, treatment classes and company portfolios.

Discover the strategies that offer the greatest success potential for CNS developers in the future and understand the challenges currently facing companies within this therapeutic area.

Publication: 39692
Library Code: rbhc0208
Type: Report
Format: PDF
Pages: 231